

## **APPENDIX I –FINANCIAL REPORT**

- Part A: Expenditures July 1<sup>st</sup>, 2009 to December 30<sup>th</sup>, 2010
- Part B: Forecast of expenditures to the end of the Project
- Part C: Variance explanations

**International Barcode of Life (iBOL) INTERIM REVIEW  
APPENDIX I - FINANCIAL DETAILS**

Genome Centre: **Ontario Genomics Institute**  
 Project Name: **International Barcode of Life (iBOL)**  
 Project Leader(s): **Paul Hebert**  
 Start Date: **1-Jul-09**

**Financial Overview - Total Expenditures (including co-funded expenditures)**

Please see the guidelines for detailed instructions.

Note that adding or deleting activity sections will necessitate changing the project total section formulas accordingly.

**Part A - Expenditures to December 31, 2010:**

<b>Activities</b>	<b>Categories</b>	<b>Total expenditures from Jul '09 to Dec '10</b>	<b>Approved budget from Jul '09 to Dec '10</b>	<b>\$ Variance (over budget)</b>	<b>% Var.</b>	<b>Note (1,2,..9) as req.</b>
-------------------	-------------------	---	--	----------------------------------	---------------	-------------------------------

Please indicate the number of fiscal quarters (Q):

(linked to B)

<b>1 - Project management</b>	Salaries	89,777	232,540	142,763	61%	<b>1</b>
	Consumables	0	0	0		
	S&T	0	0	0		
	G&A	150,648	154,811	4,163	3%	
	Equipment	0	0	0		
	International					
	<b>Total</b>		<b>240,425</b>	<b>387,351</b>	<b>146,926</b>	<b>38%</b>
<b>2 - GE3LS</b>	Salaries	0	39,781	39,781	100%	
	Consumables	0	15,000	15,000	100%	
	S&T	0	0	0		
	G&A	0	24,950	24,950	100%	
	Equipment	0	7,500	7,500	100%	
	International					
	<b>Total</b>		<b>0</b>	<b>87,231</b>	<b>87,231</b>	<b>100%</b>
<b>3 - WG1.1-1.10 (Library)</b>	Salaries	1,702,234	2,110,800	408,566	19%	<b>3</b>

	Consumables	1,712,435	2,680,288	967,853	36%	<b>4</b>
	S&T	0	0	0		
	G&A	0	0	0		
	Equipment	284,084	600,950	316,866	53%	<b>5</b>
	International	3,563,213	1,300,000	(2,263,213)	-174%	<b>6</b>
	<b>Total</b>	<b>7,261,965</b>	<b>6,692,038</b>	<b>(569,926)</b>	<b>-9%</b>	
<b>4 - WG3.1-3.2 (Informatics)</b>	Salaries	570,142	550,897	(19,245)	-3%	
	Consumables	0	0	0		
	S&T	0	0	0		
	G&A	0	0	0		
	Equipment	9,056	20,000	10,944	55%	<b>7</b>
	International					
	<b>Total</b>	<b>579,198</b>	<b>570,897</b>	<b>(8,300)</b>	<b>-1%</b>	
<b>5 - WG5.1-5.2 (Admin)</b>	Salaries	224,453	241,729	17,276	7%	
	Consumables	0	0	0		
	S&T	0	0	0		
	G&A	250,834	87,500	(163,334)	-187%	<b>8</b>
	Equipment		0	0		
	International					
	<b>Total</b>	<b>475,287</b>	<b>329,229</b>	<b>(146,058)</b>	<b>-44%</b>	
<b>PROJECT TOTAL</b>	Salaries	2,586,606	3,175,748	589,141	19%	
	Consumables	1,712,435	2,695,288	982,853	36%	
	S&T	0	0	0		
	G&A	401,482	267,261	(134,221)	-50%	
	Equipment	293,139	628,450	335,311	53%	
	International	3,563,213	1,300,000	(2,263,213)	-174%	
	<b>TOTAL</b>	<b>8,556,874</b>	<b>8,066,747</b>	<b>(490,128)</b>	<b>-6%</b>	

**Source of funding RECEIVED to December 31, 2010:**

Source of funding: For each co-funder, indicate the nature of co-funding (i.e. cash, in-kind-equipment, discounts, or other)	Nature (ie., cash, in-kind, etc.)	Total co-funding from Jul '09 to Dec '10	Approved co-funding from Jul '09 to Dec '10	\$ Variance (under budget)	% Var.	Note (1,2,..9) as req.
Genome Canada	Cash	2,801,886	3,898,384	(1,096,498)	-28%	<b>9</b>
MRI	Cash	0	2,775,322	(2,775,322)	-100%	<b>10</b>
University of Guelph	Cash	81,186	93,040	(11,854)	-13%	<b>11</b>

International samples	In-kind	3,563,213	1,300,000	2,263,213	174%	<b>12</b>
				0		
				0		
				0		
<b>TOTAL</b>		<b>6,446,285</b>	<b>8,066,747</b>	<b>(1,620,462)</b>	<b>-20%</b>	

**International Barcode of Life (IBOL) INTERIM REVIEW  
APPENDIX I - FINANCIAL DETAILS**

Genome Centre: **Ontario Genomics Institute**  
 Project Name: **International Barcode of Life (IBOL)**  
 Project Leader(s): **Paul Hebert**  
 Start Date: **1-Jul-09**

**Financial Overview - Total Expenditures (including co-funded expenditures)**

Please see the guidelines for detailed instructions.

Note that adding or deleting activity sections will necessitate changing the project total section formulas accordingly.

**Part B - Forecast Expenditures to end of project:**

Activities	Categories	Total expenditures from Jul '09 to Dec '10	Estimated expenditures for year 2	Estimated expenditures for year 3	Estimated expenditures for year 4	Estimated expenditures for year 5	Estimated expenditures for year 6	Total expenditures from Jul '09 to end date	Approved budget from Jul '09 to end date	\$ Variance (over budget)	% Var.	Note (1,2,..9) as req.
Please indicate the number of fiscal quarters (Q) : (linked fr. A)												
<b>1 - Project management</b>	Salaries	89,777	282,263	372,040	372,040	372,040	372,040	1,860,200	0	(1,860,200)		
	Consumables	0	0	0	0	0	0	0	0	0		
	S&T	0	0	0	0	0	0	0	0	0		
	G&A	150,648	158,974	309,622	309,622	309,622	309,622	1,548,110	0	(1,548,110)		
	Equipment	0	0	0	0	0	0	0	0	0		
	International	0	0	0	0	0	0	0	0	0		
	<b>Total</b>	<b>240,425</b>	<b>441,237</b>	<b>681,662</b>	<b>681,662</b>	<b>681,662</b>	<b>681,662</b>	<b>3,408,310</b>	<b>0</b>	<b>(3,408,310)</b>		
<b>2 - GE3LS</b>	Salaries	0	79,561	121,965	124,649	127,391	130,194	583,760	583,759	(1)	0%	
	Consumables	0	70,000	69,000	69,000	69,000	59,000	336,000	336,000	0	0%	
	S&T	0	0	0	0	0	0	0	0	0		
	G&A	0	9,900	9,900	9,900	9,900	9,900	49,500	49,500	0	0%	
	Equipment	0	15,000	0	15,000	0	0	30,000	30,000	0	0%	
	International	0	0	0	0	0	0	0	0	0		
	<b>Total</b>	<b>0</b>	<b>174,461</b>	<b>200,865</b>	<b>218,549</b>	<b>206,291</b>	<b>199,094</b>	<b>999,260</b>	<b>999,259</b>	<b>(1)</b>	<b>0%</b>	
<b>3 - WG1.1-1.10 (Library)</b>	Salaries	1,702,234	1,206,066	2,972,628	3,187,897	3,392,054	2,993,802	15,454,681	12,353,747	(3,100,934)	-25%	<b>13</b>
	Consumables	1,712,435	2,467,988	2,142,500	2,142,500	2,162,500	2,162,500	12,790,423	8,687,500	(4,102,923)	-47%	<b>14</b>
	S&T	0	0	0	0	0	0	0	0	0		
	G&A	0	0	0	0	0	0	0	0	0		
	Equipment	284,084	917,816	0	0	0	0	1,201,900	0	(1,201,900)		
	International	1,300,000	1,300,000	16,100,000	16,100,000	16,100,000	16,100,000	67,000,000	83,300,000	16,300,000	20%	<b>15</b>
	<b>Total</b>	<b>7,261,965</b>	<b>5,891,871</b>	<b>21,215,128</b>	<b>21,430,397</b>	<b>21,654,554</b>	<b>21,256,302</b>	<b>96,447,004</b>	<b>104,341,247</b>	<b>7,894,243</b>	<b>8%</b>	
<b>6 - WG2.1-2.4 (Methods)</b>	Salaries	0	0	532,812	544,534	556,514	539,406	2,173,266	2,155,203	(18,063)	-1%	
	Consumables	0	0	50,000	50,000	50,000	50,000	200,000	200,000	0	0%	
	S&T	0	0	0	0	0	0	0	0	0		
	G&A	0	0	0	0	0	0	0	0	0		
	Equipment	0	0	0	0	0	0	0	0	0		
	International	0	0	4,590,000	3,690,000	2,690,000	2,690,000	13,660,000	19,250,000	5,590,000	29%	<b>15</b>
	<b>Total</b>	<b>0</b>	<b>0</b>	<b>5,172,812</b>	<b>4,284,534</b>	<b>3,296,514</b>	<b>3,279,406</b>	<b>16,033,266</b>	<b>21,605,203</b>	<b>5,571,937</b>	<b>26%</b>	
<b>4 - WG3.1-3.2 (Informatics)</b>	Salaries	570,142	402,255	983,747	1,136,527	1,250,880	1,249,048	5,592,600	4,466,473	(1,126,126)	-25%	<b>16</b>
	Consumables	0	0	0	0	0	0	0	0	0		
	S&T	0	0	0	0	0	0	0	0	0		
	G&A	0	0	0	0	0	0	0	0	0		
	Equipment	9,056	30,944	500,000	0	0	0	540,000	0	(540,000)		
	International	0	0	1,350,000	1,350,000	1,350,000	1,350,000	5,400,000	8,500,000	3,100,000	36%	<b>15</b>
	<b>Total</b>	<b>579,198</b>	<b>433,200</b>	<b>2,833,747</b>	<b>2,486,527</b>	<b>2,600,880</b>	<b>2,599,048</b>	<b>11,532,600</b>	<b>12,966,473</b>	<b>1,433,874</b>	<b>11%</b>	
<b>7 - WG4.1-4.2 (Technologies)</b>	Salaries	0	0	189,417	193,584	197,843	172,845	753,689	766,184	12,495	2%	
	Consumables	0	0	300,000	300,000	300,000	300,000	1,200,000	1,200,000	0	0%	
	S&T	0	0	1,000,000	1,000,000	1,000,000	500,000	3,500,000	4,500,000	1,000,000	22%	<b>17</b>
	G&A	0	0	0	0	0	0	0	0	0		
	Equipment	0	0	0	0	0	0	0	0	0		
	International	0	0	1,900,000	1,900,000	1,900,000	1,900,000	7,600,000	9,500,000	1,900,000	20%	<b>15</b>
	<b>Total</b>	<b>0</b>	<b>0</b>	<b>3,389,417</b>	<b>3,393,584</b>	<b>3,397,843</b>	<b>2,872,845</b>	<b>13,053,689</b>	<b>15,966,184</b>	<b>2,912,495</b>	<b>18%</b>	
<b>5 - WG5.1-5.2 (Admin)</b>	Salaries	224,453	87,965	1,399,243	1,430,026	1,461,487	1,493,640	6,096,814	6,941,029	844,215	12%	<b>18</b>
	Consumables	0	0	0	0	0	0	0	0	0		
	S&T	0	0	0	0	0	0	0	0	0		
	G&A	250,834	35,000	475,000	475,000	475,000	475,000	2,185,834	2,370,000	184,166	8%	
	Equipment	0	0	0	0	0	0	0	0	0		
	International	0	0	1,200,000	1,200,000	1,200,000	1,200,000	4,800,000	7,600,000	2,800,000	37%	<b>15</b>
	<b>Total</b>	<b>475,287</b>	<b>122,965</b>	<b>3,074,243</b>	<b>3,105,026</b>	<b>3,136,487</b>	<b>3,168,640</b>	<b>13,082,648</b>	<b>16,911,029</b>	<b>3,828,381</b>	<b>23%</b>	

<b>PROJECT TOTAL</b>	Salaries	2,586,606	1,655,855	5,398,688	5,659,146	5,909,485	5,529,081	26,738,862	22,033,737	(4,134,984)	-19%	<b>Note (1,2...9) as req.</b>
	Consumables	1,712,435	2,537,988	2,261,500	2,261,500	2,281,500	2,271,500	13,326,423	9,223,500	(4,102,923)	-44%	
	S&T	0	0	0	0	0	0	0	0	0		
	G&A	401,482	203,874	794,522	794,522	794,522	794,522	3,783,444	2,419,500	(1,363,944)	-56%	
	Equipment	293,139	932,816	0	15,000	0	0	1,240,956	30,000	(1,201,900)	-4006%	
	International	3,563,213	1,300,000	21,890,000	20,990,000	19,990,000	19,990,000	87,723,213	128,150,000	298,733,213	233%	
	<b>TOTAL</b>	<b>8,556,874</b>	<b>7,063,734</b>	<b>36,567,875</b>	<b>35,600,280</b>	<b>34,974,230</b>	<b>34,056,996</b>	<b>154,556,776</b>	<b>172,789,394</b>	<b>18,232,618</b>	<b>11%</b>	

**Source of funding RECEIVED and FORECASTED to end of project:**

Source of funding: For each co-funder, indicate the nature of co-funding (i.e. cash, in-kind-equipment, discounts, or other)	Nature (ie., cash, in-kind, etc.)	Total co-funding from Jul '09 to Dec '10	Estimated co-funding to end of year 2	Estimated co-funding for year 3	Estimated co-funding for year 4	Estimated co-funding for year 5	Estimated co-funding for year 6	Total co-funding from Jul '09 to end date	Approved from Start	co-funding to end date	\$ Variance (under budget)	% Var.	
Genome Canada	Cash	2,801,886	3,798,114	4,600,000	4,600,000	4,600,000	4,600,000	25,000,000	25,000,000	25,000,000	0	0%	
MRI	Cash	5,000,000	1,220,000	1,220,000	1,220,000	1,220,000	1,220,000	11,100,000	4,763,524	6,336,476	6,336,476	133%	<b>19</b>
University of Guelph	Cash	81,186						81,186	93,040	(11,854)	(11,854)	-13%	<b>11</b>
International samples	In-kind	3,563,213	1,300,000	4,500,000	4,500,000	4,500,000	4,500,000	22,863,213	20,600,000	2,263,213	2,263,213	11%	<b>6</b>
CFI-IOF	Cash			460,000	460,000	460,000		1,380,000	1,483,523	(103,523)	(103,523)	-7%	
IDRC			239,275	287,275	183,350			709,900		709,900	709,900		
IBOL Node funding	Cash							93,422,478	107,550,000	(14,127,522)	(14,127,522)	-13%	
<b>TOTAL</b>		<b>6,446,285</b>	<b>6,557,389</b>	<b>11,067,275</b>	<b>10,963,350</b>	<b>10,780,000</b>	<b>10,320,000</b>	<b>154,556,776</b>	<b>159,490,087</b>	<b>(4,933,311)</b>	<b>(4,933,311)</b>	<b>-3%</b>	

**International Barcode of Life (iBOL) INTERIM REVIEW  
APPENDIX I - FINANCIAL DETAILS**

Genome Centre: **Ontario Genomics Institute**  
 Project Name: **International Barcode of Life (iBOL)**  
 Project Leader(s): **Paul Hebert**  
 Start Date: **1-Jul-09**

**Part C - Actual and Forecast Expenditures Variances:**

Ref. #	Variance explanations
1	Two salaries are budgeted for this line item: the iBOL Executive Director, and the Project Manager. The ED started shortly into Y2, resulting in some discrepancy between the budget and actual expenses. More significantly, a portion of the ED's salary comes as a performance bonus, paid at the end of the contract. This expense will not be realized until later in the year. The University of Guelph agreed to pay one year of the PM's salary, from Feb 09 to Feb 10. Between Feb 10 and Apr 10 this salary was paid from Genome Canada funds. However, a grant from the IDRC has funded this position thereafter.
2	GE3LS research is taking place at other institutions (Concordia, McGill, U. Alberta, and U. Saskatchewan). The U. of Guelph is unable to transfer funds to these other institutions until a contract is in place between the U of G and Genome Canada---which has not taken place yet (as of Feb 8 2011)
3	During the reporting period, \$3.9 million was expected from Genome Canada but only \$1.2 was received, creating a large deficit balance (see item 9, below). To mitigate this, other grant accounts (ineligible co-funding, not reported here) were used to supplement these salary expenses.
4	As noted above in item 3, consumables were expensed to other grant accounts in lieu of Genome Canada funding.
5	A liquid handling robot (approximate cost: \$500,000) was budgeted for fall of 2010 and a PO was issued. However, the expense did not appear on the account during the reporting period.
6	A large part of this variance is because samples received from international collaborators were not counted as co-funding in our Y1 budget (but we still count them here as a contribution). For Year 2, we could only provide letters of intent for 260,000 samples. However, we now project that we will receive approximately twice that number, having received nearly the annual budgeted amount in the first six months.
7	Computer expenses have been budgeted equally across quarters, whereas actual expenses are anticipated to take place later in the year.
8	A Scientific Steering Committee occurred early in Fall 2010 that used the majority of the year's budgeted G&A expenses for Project Management and Administration. G&A expenses in the second half of Year 2 will be much lower, but we are still projecting to exceed the budget for the Project Management and Administration G&A lines.

9	Funding irregularities in both Years 1 and 2 have caused a large variance here. In Year 1, some Working Groups exceeded their targets while others did not meet their targets. Genome Canada compensates the Project \$75 for each new species barcoded, but only up to the budgeted amount per working group. Therefore, while overall targets were exceeded (more than 30,000 new species were barcoded when the target was 20,000), variances on a WG-by-WG level caused only \$1.1 million of the budgeted \$2 million to be received. The remaining funds have rolled over to the Year 2 budget. However, delays in budget negotiation prevented initial funds from being transferred until late December 2010.
10	A one-time \$5 million award was received from the Ontario Ministry of Research and Innovation in 2008 that is meant to be used over the course of the iBOL project. Because all funds were received prior to the reporting period of this document, revenues are shown as \$0.
11	The iBOL year runs July 1st to June 30th, but (as noted in Item 1, above), the University's contribution started February 2009 and ran through to February 2010.
12	See Item #6, above.
PART B	Large discrepancies exist because there are multiple "approved budgets". A revised budget was prepared for the Board of Directors in January 2009, in response to the initial review of the Project. This budget serves as the source for most of the figures in Part B. However, since June 2009 the Project has been funded on a year-to-year basis, with a new budget and budget negotiations occurring annually. Most recently, in Feb 2011 a budget was approved by Genome Canada covering the period from July 2009 through to June 30th, 2011. The approved budget amounts through to the end of Year 2 presented in Part B are taken from this budget, and should be considered the most accurate projections in that table. Finally, a separate 5-year GE3LS budget was approved by Genome Canada in mid-2010, which provides the approved figures presented in Part B for the GE3LS activity.
13	The original 2008 budget had very little work being accomplished in Year 1, but in fact more than 200,000 samples were processed. In addition, the original budget assumed that technology improvements would allow more samples to be processed at Canada's core facility with the same level of human effort. While improvements have been made (e.g., a 100% increase in production was realized in 2009 with minimal staffing increases), we have not been able to keep staffing levels constant while increasing production.
14	As in Line 13, the cost of consumables was expected to be low in Year 1 but instead we launched into full production. In addition, we expected that technological improvements would allow more samples to be processed for a constant consumables expense.
15	This line represents a conflation of two values: the in-kind value of specimens received at the Canadian core facility, and funds raised (and used) internationally to support the Project. Currently, no mechanism exists for the accounting of the latter, resulting in lower-than-forecasted values being reported in years 1 and 2. Procedures are being developed for more closely tracking international expenses.
16	As noted in Lines 13 and 14, above, the original budget had little activity taking place in Year 1 (the salary budget for that year was only \$200K). However, the project started full-force with full staffing in Year 1.

17	WG4.2 has been off to a slow start. A meeting of experts in DNA sequences and genomics took place in February 2009, but attendants were in general agreement that the time was not right for the development of this device. Therefore, industry investment has been lower than originally projected. Nevertheless, after recent talks with Life Technologies we are optimistic about this Working Group meeting its goals.
18	Certain administrative positions (e.g., CFO, Financial Director) have been deemed unnecessary at this stage in the Project, although they remain part of the budget for years 3-6.
19	A new award from MRI has increased the level of support available from that organization.
20	This activity was not part of the original (2008) iBOL Budget.